Anti-Human IL-31 Reference Antibody (Riltovetbart, RUO)
- Catalog number: BS11426
- Availability: In Stock
$370.00
- Ex Tax: $370.00
Description: Riltovetbart (BS11426) is a research-grade recombinant antibody targeting IL-31. Produced in mammalian cells with native-like glycosylation.
Highlights:
• Research Grade — For PK/PD studies, assay development, and ADA research.
• Native Glycosylation — Mammalian expression ensures native-like patterns.
Host species: Caninized
Isotype: IgG2-kappa
Species reactivity: Dog
Immunogen:
Form: Liquid
Storage instructions:
Storage buffer: 0.01M PBS, pH7.4.
Concentration: 1mg/ml
Purity: >95% as determined by SDS-PAGE.
Clonality: Monoclonal
Applications: Research Grade Biosimilar
Target: IL-31,Interleukin-31,IL31
Purification: Protein A/G purified from cell culture supernatant.
Endotoxin level: <1EU/mg, determined by LAL gel clotting assay
Expression system: Mammalian Cells
Stability and Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names: CAS:2641479-65-2
Background: Tirnovetmab (KIND-016) is an antibody. Tirnovetmab can be used for experiment research.
References:
1. The IL-4, IL-13 and IL-31 pathways in atopic dermatitis., PMID:34106037
2. IL-31-dependent neurogenic inflammation restrains cutaneous type 2 immune response in allergic dermatitis., PMID:37831760
3. Interleukin-31: The "itchy" cytokine in inflammation and therapy., PMID:33629401
4. A sensory neuron-expressed IL-31 receptor mediates T helper cell-dependent itch: Involvement of TRPV1 and TRPA1., PMID:24373353
5. Seladelpar treatment reduces IL-31 and pruritus in patients with primary biliary cholangitis., PMID:38117036
2. Nemolizumab: First Approval., PMID:35834124
7. Nemolizumab: An Innovative Biologic Treatment to Control Interleukin 31, a Key Mediator in Atopic Dermatitis and Prurigo Nodularis., PMID:35842249
8. The Cytokine TGF-β Induces Interleukin-31 Expression from Dermal Dendritic Cells to Activate Sensory Neurons and Stimulate Wound Itching., PMID:32673566
3. Pruritus as a Distinctive Feature of Type 2 Inflammation., PMID:33807098
4. Targeting Interleukin-31 in Prurigo., PMID:37888922
Note: For research use only. Not suitable for clinical or therapeutic use.
Highlights:
• Research Grade — For PK/PD studies, assay development, and ADA research.
• Native Glycosylation — Mammalian expression ensures native-like patterns.
Host species: Caninized
Isotype: IgG2-kappa
Species reactivity: Dog
Immunogen:
Form: Liquid
Storage instructions:
Storage buffer: 0.01M PBS, pH7.4.
Concentration: 1mg/ml
Purity: >95% as determined by SDS-PAGE.
Clonality: Monoclonal
Applications: Research Grade Biosimilar
Target: IL-31,Interleukin-31,IL31
Purification: Protein A/G purified from cell culture supernatant.
Endotoxin level: <1EU/mg, determined by LAL gel clotting assay
Expression system: Mammalian Cells
Stability and Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names: CAS:2641479-65-2
Background: Tirnovetmab (KIND-016) is an antibody. Tirnovetmab can be used for experiment research.
References:
1. The IL-4, IL-13 and IL-31 pathways in atopic dermatitis., PMID:34106037
2. IL-31-dependent neurogenic inflammation restrains cutaneous type 2 immune response in allergic dermatitis., PMID:37831760
3. Interleukin-31: The "itchy" cytokine in inflammation and therapy., PMID:33629401
4. A sensory neuron-expressed IL-31 receptor mediates T helper cell-dependent itch: Involvement of TRPV1 and TRPA1., PMID:24373353
5. Seladelpar treatment reduces IL-31 and pruritus in patients with primary biliary cholangitis., PMID:38117036
2. Nemolizumab: First Approval., PMID:35834124
7. Nemolizumab: An Innovative Biologic Treatment to Control Interleukin 31, a Key Mediator in Atopic Dermatitis and Prurigo Nodularis., PMID:35842249
8. The Cytokine TGF-β Induces Interleukin-31 Expression from Dermal Dendritic Cells to Activate Sensory Neurons and Stimulate Wound Itching., PMID:32673566
3. Pruritus as a Distinctive Feature of Type 2 Inflammation., PMID:33807098
4. Targeting Interleukin-31 in Prurigo., PMID:37888922
Note: For research use only. Not suitable for clinical or therapeutic use.
Images
-
SDS-PAGESDS-PAGE for Research Grade Riltovetbart
